Gefitinib – Uses, Dosage, Side Effects, Interaction Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in the inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in the inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04) Gefitinib is a medication used for certain breast, lung, and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistance to gefitinib can arise through other mutations. It is marketed by AstraZeneca and Teva. Gefitinib is a selective tyrosine kinase receptor inhibitor used in the therapy of non-small cell lung cancer. Gefitinib therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury. Gefitinib is a member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer. It has a role as an epidermal growth factor receptor antagonist and an antineoplastic agent. It is an aromatic ether, a member of monochlorobenzenes, a member of monofluorobenzenes, a secondary amino compound, a tertiary amine compound, a member of quinazolines, and a member of morpholines. Mechanism of Action Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-the binding site of the enzyme. EGFR is often shown to be overexpressed in certain human carcinoma cells, such as lung and breast cancer cells. Overexpression leads to enhanced activation of the anti-apoptotic Ras signal transduction cascades, subsequently resulting in increased survival of cancer cells and uncontrolled cell proliferation. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. By inhibiting EGFR tyrosine kinase, the downstream signaling cascades are also inhibited, resulting in inhibited malignant cell proliferation. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells. or Gefitinib is the first selective inhibitor of epidermal growth factor receptor’s (EGFR) tyrosine kinase domain. Thus gefitinib is an EGFR inhibitor. The target protein (EGFR) is a member of a family of receptors (ErbB) which includes Her1(EGFR), Her2(Erb-B2), Her3(Erb-B3), and Her4 (Erb-B4). EGFR is overexpressed in the cells of certain types of human carcinomas – for example in lung and breast cancers. This leads to inappropriate activation of the anti-apoptotic Ras signaling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitinib-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways.[rx][rx] These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitinib and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. These mutations are more commonly seen in Asians, women, and non-smokers (who also tend to more often have adenocarcinoma). Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-the binding site of the enzyme.[rx] Thus the function of the EGFR tyrosine kinase in activating the anti-apoptotic Ras signal transduction cascade is inhibited, and malignant cells are inhibited.[rx] Indications For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies. Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase. Gefitinib is a selective tyrosine kinase receptor inhibitor used in the therapy of non-small cell lung cancer. Gefitinib is used to treat non-small cell lung cancer that has spread to other parts of the body in people with certain types of tumors. Gefitinib is in a class of medications called kinase inhibitors. In Europe, gefitinib is indicated since 2009 in advanced NSCLC in all lines of treatment for patients harboring EGFR mutations. This label was granted after gefitinib was demonstrated as a first-line treatment to significantly improve progression-free survival vs. a platinum doublet regime in patients harboring such mutations. IPASS has been the first of four phases III trials to have confirmed gefitinib superiority in this patient population. IRESSA is contraindicated in patients with severe hypersensitivity to gefitinib or to any other component of IRESSA. Use in Cancer Gefitinib is approved to treat: Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR gene mutations. Gefitinib is also being studied in the treatment of other types of cancer. Contraindications a type of inflammation of the lung called interstitial pneumonitis a condition where there is a formation of fibrous tissue in the lung called pulmonary fibrosis liver problems severe renal impairment pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: 250 mg Non-Small Cell Lung Cancer 250 mg orally once a day until disease progression or unacceptable toxicity Select patients for the first-line treatment of metastatic NSCLC with this drug based on the presence of EGFR exon 19 deletions or exon 21 L858R mutations in their tumor or plasma specimens. NOTE: For patients who have difficulty swallowing tablets immerse the tablet in 4 to 8 ounces of water (noncarbonated) and stir until dispersed (about 15 minutes). Drink the liquid or administer through a nasogastric tube. Rinse the container with 4 to 8 ounces of water and drink or administer through nasogastric tube. Dose Adjustments Withhold therapy for up to 14 days for the following adverse drug reactions and resume when fully resolved to Grade 1: Acute onset or worsening of pulmonary symptoms (e.g., dyspnea, cough, fever) Grade 2 or higher in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevations Grade 3 or higher diarrhea Severe or worsening ocular disorders including keratitis Grade 3 or higher skin reactions Permanently discontinue therapy for: Confirmed interstitial lung disease (ILD) Severe hepatic impairment GI perforation Persistent ulcerative keratitis Concomitant use with strong CYP450 3A4 inducers: Avoid concomitant use if possible. If concomitant use is required, increase dose to 500 mg orally once a day (in the absence of severe adverse drug reaction); resume at 250 mg dose 7 days after discontinuation of the strong CYP450 3A4 inducer. Concomitant use with proton-pump inhibitor/H2 receptor antagonist/antacid: Avoid concomitant use if possible. If concomitant use is required, take this drug 12 hours after the last dose of the proton-pump inhibitor or 12 hours before the next dose of the proton-pump inhibitor. Take this drug 6 hours after the last dose of the H2-receptor antagonist or antacid, or 6 hours before the next dose of the H2-receptor antagonist or antacid. Administration Advice: Therapy should be initiated and supervised by a physician experienced in the use of anticancer therapies. This drug should be taken at about the same time each day, with or without food. A missed dose should not be taken within 12 hours of the next dose. Side Effects The Most Common dry skin itching rash acne mouth sores weakness new or worsening shortness of breath, cough, or fever severe or ongoing diarrhea severe abdominal pain loss of appetite eye pain, redness, or irritation vision changes watery eyes eye sensitivity to light hives blisters or peeling skin swelling of the eyes, face, lips, tongue, throat, hands, arms, feet, ankles or lower legs nausea vomiting yellowing of the skin or eyes dark urine pale stools pain or discomfort in the right upper stomach area More common Abdominal or stomach pain or tenderness clay-colored stools dark urine decreased appetite diarrhea, severe fever headache itching or skin rash loss of appetite nausea and vomiting swelling of the feet or lower legs unusual tiredness or weakness yellow eyes or skin Burning, dry, or itching eyes chest pain chills cough difficult breathing discharge or excessive tearing dry eyes a general feeling of discomfort or illness redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid thickening of bronchial secretions troubled breathing troubled or quick, shallow breathing Rare severe or ongoing diarrhea; sudden chest pain or discomfort, new or worsening cough with fever, trouble breathing; blurred vision, watery eyes, eye pain or redness, eyes being more sensitive to light; liver problems–nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); signs of stomach bleeding–severe stomach pain, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds; or severe skin reaction–fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling. Blistering, peeling, or loosening of the skin bloody, black, or tarry stools eye redness, irritation, or pain heartburn indigestion joint or muscle pain red skin lesions, often with a purple center severe abdominal or stomach pain, cramping, or burning sore throat sores, ulcers, or white spots in the mouth or on the lips vomiting of material that looks like coffee grounds, severe and continuing Drug Interactions DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Gefitinib. Abametapir The serum concentration of Gefitinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Gefitinib can be increased when combined with Abatacept. Abemaciclib Gefitinib may decrease the excretion rate of Abemaciclib which could result in a higher serum level. Abiraterone The metabolism of Gefitinib can be decreased when combined with Abiraterone. Acalabrutinib The metabolism of Gefitinib can be decreased when combined with Acalabrutinib. Acebutolol The metabolism of Gefitinib can be decreased when combined with Acebutolol. Acenocoumarol Gefitinib may increase the anticoagulant activities of Acenocoumarol. Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Gefitinib. Adalimumab The metabolism of Gefitinib can be increased when combined with Adalimumab. Afatinib Gefitinib may decrease the excretion rate of Afatinib which could result in a higher serum level. Alectinib Alectinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Alfentanil The metabolism of Alfentanil can be decreased when combined with Gefitinib. Allopurinol Gefitinib may decrease the excretion rate of Allopurinol which could result in a higher serum level. Almasilate Almasilate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Almotriptan The metabolism of Almotriptan can be decreased when combined with Gefitinib. Alogliptin The metabolism of Alogliptin can be decreased when combined with Gefitinib. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Gefitinib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Gefitinib. Aluminium Aluminium phosphate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum Aluminum hydroxide can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Gefitinib. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Gefitinib. Amiodarone The metabolism of Gefitinib can be decreased when combined with Amiodarone. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Gefitinib. Amoxapine The metabolism of Amoxapine can be decreased when combined with Gefitinib. Amphetamine The metabolism of Amphetamine can be decreased when combined with Gefitinib. Amprenavir The metabolism of Gefitinib can be decreased when combined with Amprenavir. Anakinra The metabolism of Gefitinib can be increased when combined with Anakinra. Antipyrine The metabolism of Antipyrine can be decreased when combined with Gefitinib. Apalutamide The metabolism of Gefitinib can be increased when combined with Apalutamide. Apixaban Gefitinib may decrease the excretion rate of Apixaban which could result in a higher serum level. Apomorphine The metabolism of Apomorphine can be decreased when combined with Gefitinib. Apremilast The metabolism of Gefitinib can be increased when combined with Apremilast. Aprepitant The metabolism of Gefitinib can be decreased when combined with Aprepitant. Arformoterol The metabolism of Arformoterol can be decreased when combined with Gefitinib. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Gefitinib. Aripiprazole The metabolism of Aripiprazole lauroxil can be decreased when combined with Gefitinib. Armodafinil The metabolism of Gefitinib can be increased when combined with Armodafinil. Artemether The metabolism of Artemether can be decreased when combined with Gefitinib. Artenimol The metabolism of Gefitinib can be decreased when combined with Artenimol. Articaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Articaine. Asenapine Asenapine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Astemizole The metabolism of Astemizole can be decreased when combined with Gefitinib. Asunaprevir The metabolism of Gefitinib can be decreased when combined with Asunaprevir. Atazanavir The metabolism of Gefitinib can be decreased when combined with Atazanavir. Atenolol The metabolism of Atenolol can be decreased when combined with Gefitinib. Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Gefitinib. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Gefitinib. Avanafil The serum concentration of Avanafil can be increased when it is combined with Gefitinib. Avatrombopag Avatrombopag may decrease the excretion rate of Gefitinib which could result in a higher serum level. Axitinib The metabolism of Axitinib can be decreased when combined with Gefitinib. Azelastine The metabolism of Gefitinib can be decreased when combined with Azelastine. Beclomethasone Beclomethasone dipropionate may decrease the excretion rate of Gefitinib which could result in a higher serum level. Belumosudil Belumosudil may decrease the excretion rate of Gefitinib which could result in a higher serum level. Benzatropine The metabolism of Benzatropine can be decreased when combined with Gefitinib. Benzocaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Benzyl alcohol. Bepridil The metabolism of Gefitinib can be decreased when combined with Bepridil. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Gefitinib. Betamethasone The metabolism of Gefitinib can be increased when combined with Betamethasone. Betamethasone The metabolism of Gefitinib can be increased when combined with Betamethasone phosphate. Betaxolol The metabolism of Betaxolol can be decreased when combined with Gefitinib. Bimekizumab The metabolism of Gefitinib can be increased when combined with Bimekizumab. Biperiden The metabolism of Gefitinib can be decreased when combined with Biperiden. Bismuth Bismuth subnitrate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Boceprevir The metabolism of Gefitinib can be decreased when combined with Boceprevir. Bortezomib The metabolism of Bortezomib can be decreased when combined with Gefitinib. Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Gefitinib. Brigatinib Gefitinib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Budesonide The metabolism of Gefitinib can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Bupivacaine. Buprenorphine Buprenorphine may decrease the excretion rate of Gefitinib which could result in a higher serum level. Bupropion The metabolism of Gefitinib can be decreased when combined with Bupropion. Buspirone The metabolism of Buspirone can be decreased when combined with Gefitinib. Butacaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Gefitinib. Caffeine Caffeine may decrease the excretion rate of Gefitinib which could result in a higher serum level. Calcium Calcium carbonate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Canakinumab The metabolism of Gefitinib can be increased when combined with Canakinumab. Cannabidiol Cannabidiol may decrease the excretion rate of Gefitinib which could result in a higher serum level. Capmatinib The serum concentration of Gefitinib can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Capsaicin. Carbamazepine The metabolism of Gefitinib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Gefitinib. Carvedilol The metabolism of Carvedilol can be decreased when combined with Gefitinib. Celecoxib The metabolism of Gefitinib can be decreased when combined with Celecoxib. Celiprolol The metabolism of Celiprolol can be decreased when combined with Gefitinib. Cenobamate The serum concentration of Gefitinib can be decreased when it is combined with Cenobamate. Cerivastatin Gefitinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level. Certolizumab The metabolism of Gefitinib can be increased when combined with Certolizumab pegol. Cevimeline The metabolism of Cevimeline can be decreased when combined with Gefitinib. Chloramphenicol The metabolism of Gefitinib can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Chloroprocaine. Chloroquine The metabolism of Gefitinib can be decreased when combined with Chloroquine. Chlorpheniramine The metabolism of Gefitinib can be decreased when combined with Chlorpheniramine. Chlorpromazine The metabolism of Gefitinib can be decreased when combined with Chlorpromazine. Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Gefitinib. Cholecalciferol The metabolism of Gefitinib can be decreased when combined with Cholecalciferol. You Might Also Read Carbapenem - Uses, Dosage, Side Effects, Interactions Cholesterol Cholesterol may increase the excretion rate of Gefitinib which could result in a lower serum level and potentially a reduction in efficacy. Ciclesonide The metabolism of Ciclesonide can be decreased when combined with Gefitinib. Cilostazol The metabolism of Cilostazol can be decreased when combined with Gefitinib. Cimetidine Cimetidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Cinacalcet The metabolism of Gefitinib can be decreased when combined with Cinacalcet. Cinchocaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Cinchocaine. Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Gefitinib. Ciprofloxacin The metabolism of Gefitinib can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Gefitinib can be decreased when combined with Cisapride. Citalopram The metabolism of Gefitinib can be decreased when combined with Citalopram. Cladribine Gefitinib may decrease the excretion rate of Cladribine which could result in a higher serum level. Clarithromycin The metabolism of Gefitinib can be decreased when combined with Clarithromycin. Clemastine The metabolism of Gefitinib can be decreased when combined with Clemastine. Clevidipine The metabolism of Clevidipine can be decreased when combined with Gefitinib. Clindamycin The metabolism of Clindamycin can be decreased when combined with Gefitinib. Clobazam The metabolism of Gefitinib can be decreased when combined with Clobazam. Clobetasol The metabolism of Gefitinib can be increased when combined with Clobetasol propionate. Clofarabine Gefitinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine Clofazimine may decrease the excretion rate of Gefitinib which could result in a higher serum level. Clomipramine The metabolism of Clomipramine can be decreased when combined with Gefitinib. Clonidine The metabolism of Clonidine can be decreased when combined with Gefitinib. Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Gefitinib. Clozapine The metabolism of Gefitinib can be decreased when combined with Clozapine. Cobicistat The metabolism of Gefitinib can be decreased when combined with Cobicistat. Cocaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Cocaine. Codeine The metabolism of Codeine can be decreased when combined with Gefitinib. Conivaptan The metabolism of Gefitinib can be decreased when combined with Conivaptan. Conjugated Gefitinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib The metabolism of Copanlisib can be decreased when combined with Gefitinib. Cortisone The metabolism of Gefitinib can be increased when combined with Cortisone acetate. Crizotinib The metabolism of Crizotinib can be decreased when combined with Gefitinib. Curcumin The metabolism of Gefitinib can be decreased when combined with Curcumin. Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Gefitinib. Cyclosporine The metabolism of Gefitinib can be decreased when combined with Cyclosporine. Dabrafenib The serum concentration of Gefitinib can be decreased when it is combined with Dabrafenib. Daclatasvir Daclatasvir may decrease the excretion rate of Gefitinib which could result in a higher serum level. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Gefitinib. Dactinomycin Gefitinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Danazol The metabolism of Gefitinib can be decreased when combined with Danazol. Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Gefitinib. Dapsone The metabolism of Gefitinib can be decreased when combined with Dapsone. Darbepoetin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gefitinib. Darifenacin The metabolism of Gefitinib can be decreased when combined with Darifenacin. Darolutamide The serum concentration of Gefitinib can be increased when it is combined with Darolutamide. Darunavir The metabolism of Gefitinib can be decreased when combined with Darunavir. Dasabuvir Dasabuvir may decrease the excretion rate of Gefitinib which could result in a higher serum level. Dasatinib The metabolism of Dasatinib can be decreased when combined with Gefitinib. Daunorubicin Gefitinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Debrisoquine The metabolism of Debrisoquine can be decreased when combined with Gefitinib. Delafloxacin Gefitinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Delavirdine The metabolism of Gefitinib can be decreased when combined with Delavirdine. Desipramine The metabolism of Gefitinib can be decreased when combined with Desipramine. Desvenlafaxine The metabolism of Gefitinib can be decreased when combined with Desvenlafaxine. Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Gefitinib. Dexamethasone The metabolism of Gefitinib can be increased when combined with Dexamethasone. Dexamethasone Dexamethasone acetate may decrease the excretion rate of Gefitinib which could result in a higher serum level. Dexchlorpheniram The metabolism of Gefitinib can be decreased when combined with Dexchlorpheniramine maleate. Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Gefitinib. Dexlansoprazole Dexlansoprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Dexmedetomidine The metabolism of Gefitinib can be decreased when combined with Dexmedetomidine. Dextroamphetam The metabolism of Dextroamphetamine can be decreased when combined with Gefitinib. Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Gefitinib. Dextropropoxy The metabolism of Gefitinib can be decreased when combined with Dextropropoxyphene. Diacerein The metabolism of Gefitinib can be decreased when combined with Diacerein. Diazepam The metabolism of Diazepam can be decreased when combined with Gefitinib. Dicoumarol Gefitinib may increase the anticoagulant activities of Dicoumarol. Diethylstilbestrol Diethylstilbestrol may decrease the excretion rate of Gefitinib which could result in a higher serum level. Difluocortolone The metabolism of Gefitinib can be increased when combined with Difluocortolone. Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Gefitinib. Diltiazem The metabolism of Gefitinib can be decreased when combined with Diltiazem. Dimethyl sulfoxide The metabolism of Gefitinib can be decreased when combined with Dimethyl sulfoxide. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Diphenhydramine. Disulfiram The metabolism of Disulfiram can be decreased when combined with Gefitinib. Docetaxel The metabolism of Docetaxel can be decreased when combined with Gefitinib. Dolasetron The metabolism of Dolasetron can be decreased when combined with Gefitinib. Dolutegravir Gefitinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The metabolism of Domperidone can be decreased when combined with Gefitinib. Donepezil Gefitinib may decrease the excretion rate of Donepezil which could result in a higher serum level. Doravirine The metabolism of Doravirine can be decreased when combined with Gefitinib. Dosulepin The metabolism of Gefitinib can be decreased when combined with Dosulepin. Doxazosin The metabolism of Doxazosin can be decreased when combined with Gefitinib. Doxepin Doxepin can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Doxorubicin Gefitinib may decrease the excretion rate of Doxorubicin which could result in a higher serum level. Dronabinol The metabolism of Gefitinib can be decreased when combined with Dronabinol. Dronedarone The metabolism of Gefitinib can be decreased when combined with Dronedarone. Duloxetine The metabolism of Gefitinib can be decreased when combined with Duloxetine. Dutasteride The metabolism of Dutasteride can be decreased when combined with Gefitinib. Duvelisib Gefitinib may decrease the excretion rate of Duvelisib which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Dyclonine. Efavirenz The metabolism of Gefitinib can be decreased when combined with Efavirenz. Elagolix The metabolism of Elagolix can be decreased when combined with Gefitinib. Elbasvir Elbasvir may decrease the excretion rate of Gefitinib which could result in a higher serum level. Eletriptan The metabolism of Eletriptan can be decreased when combined with Gefitinib. Elexacaftor The metabolism of Elexacaftor can be decreased when combined with Gefitinib. Eliglustat The metabolism of Gefitinib can be decreased when combined with Eliglustat. Eltrombopag Eltrombopag may decrease the excretion rate of Gefitinib which could result in a higher serum level. Elvitegravir The metabolism of Gefitinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Gefitinib can be increased when combined with Emapalumab. Enasidenib The metabolism of Enasidenib can be decreased when combined with Gefitinib. Encainide The metabolism of Encainide can be decreased when combined with Gefitinib. Encorafenib The metabolism of Encorafenib can be decreased when combined with Gefitinib. Entacapone The metabolism of Gefitinib can be decreased when combined with Entacapone. Enzalutamide The metabolism of Gefitinib can be increased when combined with Enzalutamide. Epinastine Epinastine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Eplerenone The metabolism of Eplerenone can be decreased when combined with Gefitinib. Ergotamine The metabolism of Gefitinib can be decreased when combined with Ergotamine. Erlotinib The metabolism of Erlotinib can be decreased when combined with Gefitinib. Ertugliflozin Gefitinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The metabolism of Gefitinib can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gefitinib. Escitalopram The serum concentration of Gefitinib can be increased when it is combined with Escitalopram. Esmolol The metabolism of Esmolol can be decreased when combined with Gefitinib. Esomeprazole Esomeprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Estradiol Estradiol may decrease the excretion rate of Gefitinib which could result in a higher serum level. Estradiol acetate Estradiol acetate may decrease the excretion rate of Gefitinib which could result in a higher serum level. Estradiol Estradiol benzoate may decrease the excretion rate of Gefitinib which could result in a higher serum level. Estradiol Estradiol cypionate may decrease the excretion rate of Gefitinib which could result in a higher serum level. Estradiol Estradiol dienanthate may decrease the excretion rate of Gefitinib which could result in a higher serum level. Estradiol Estradiol valerate may decrease the excretion rate of Gefitinib which could result in a higher serum level. Etanercept The metabolism of Gefitinib can be increased when combined with Etanercept. Ethambutol The metabolism of Gefitinib can be decreased when combined with Ethambutol. Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Gefitinib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Etidocaine. Etoposide The metabolism of Etoposide can be decreased when combined with Gefitinib. Etoricoxib The metabolism of Gefitinib can be decreased when combined with Etoricoxib. Everolimus The metabolism of Gefitinib can be decreased when combined with Everolimus. Ezetimibe Gefitinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Famotidine Famotidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Febuxostat The excretion of Gefitinib can be decreased when combined with Febuxostat. Fedratinib Fedratinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Felodipine The metabolism of Gefitinib can be decreased when combined with Felodipine. Fenfluramine The metabolism of Gefitinib can be decreased when combined with Fenfluramine. Fesoterodine The metabolism of Fesoterodine can be decreased when combined with Gefitinib. Fexinidazole The metabolism of Fexinidazole can be decreased when combined with Gefitinib. Finasteride The metabolism of Finasteride can be decreased when combined with Gefitinib. Flecainide The metabolism of Flecainide can be decreased when combined with Gefitinib. Fluconazole The metabolism of Gefitinib can be decreased when combined with Fluconazole. Fluindione Gefitinib may increase the anticoagulant activities of Fluindione. Flunarizine The metabolism of Flunarizine can be decreased when combined with Gefitinib. Fluocinonide The metabolism of Gefitinib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Gefitinib can be increased when combined with Fluocortolone. Fluorouracil Gefitinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. Fluoxetine The serum concentration of Gefitinib can be increased when it is combined with Fluoxetine. Fluphenazine The metabolism of Gefitinib can be decreased when combined with Fluphenazine. Flutamide The metabolism of Flutamide can be decreased when combined with Gefitinib. Fluticasone The metabolism of Gefitinib can be decreased when combined with Fluticasone. Fluticasone The metabolism of Gefitinib can be decreased when combined with Fluticasone furoate. Fluticasone The metabolism of Gefitinib can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Gefitinib. Fluvoxamine The metabolism of Gefitinib can be decreased when combined with Fluvoxamine. Folic acid Gefitinib may decrease the excretion rate of Folic acid which could result in a higher serum level. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Gefitinib. Formoterol The metabolism of Formoterol can be decreased when combined with Gefitinib. Fosnetupitant The metabolism of Gefitinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Gefitinib can be increased when combined with Fosphenytoin. Fostamatinib Fostamatinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Fostemsavir Gefitinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level. Fusidic acid The metabolism of Gefitinib can be decreased when combined with Fusidic acid. Galantamine The metabolism of Galantamine can be decreased when combined with Gefitinib. Gilteritinib Gilteritinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Givosiran The serum concentration of Gefitinib can be increased when it is combined with Givosiran. Glasdegib Gefitinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. Glecaprevir Gefitinib may decrease the excretion rate of Glecaprevir which could result in a higher serum level. Glyburide Gefitinib may decrease the excretion rate of Glyburide which could result in a higher serum level. Glycerol The metabolism of Gefitinib can be decreased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Gefitinib can be increased when combined with Golimumab. Grazoprevir Grazoprevir may decrease the excretion rate of Gefitinib which could result in a higher serum level. Halofantrine The metabolism of Gefitinib can be decreased when combined with Halofantrine. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Gefitinib. Hydrocodone The metabolism of Hydrocodone can be decreased when combined with Gefitinib. Hydrocortisone The metabolism of Hydrocortisone can be decreased when combined with Gefitinib. Hydrocortisone The metabolism of Hydrocortisone acetate can be decreased when combined with Gefitinib. Hydrocortisone The metabolism of Hydrocortisone butyrate can be decreased when combined with Gefitinib. Hydrocortisone The metabolism of Hydrocortisone cypionate can be decreased when combined with Gefitinib. Hydrocortisone The metabolism of Hydrocortisone phosphate can be decreased when combined with Gefitinib. Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Hydroxychloroquine The metabolism of Gefitinib can be decreased when combined with Hydroxychloroquine. Hydroxyprogester The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Gefitinib. Hydroxyzine The metabolism of Gefitinib can be decreased when combined with Hydroxyzine. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Gefitinib. Idarubicin The metabolism of Idarubicin can be decreased when combined with Gefitinib. Idelalisib Gefitinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Gefitinib. Iloperidone The metabolism of Iloperidone can be decreased when combined with Gefitinib. Imatinib The serum concentration of Gefitinib can be increased when it is combined with Imatinib. Imipramine The metabolism of Gefitinib can be decreased when combined with Imipramine. Indinavir The metabolism of Gefitinib can be decreased when combined with Indinavir. Infliximab The metabolism of Gefitinib can be increased when combined with Infliximab. Ipecac The metabolism of Ipecac can be decreased when combined with Gefitinib. Irinotecan Gefitinib may decrease the excretion rate of Irinotecan which could result in a higher serum level. Isavuconazole The metabolism of Gefitinib can be decreased when combined with Isavuconazole. Isavuconazonium The metabolism of Gefitinib can be decreased when combined with Isavuconazonium. Isoniazid The metabolism of Gefitinib can be decreased when combined with Isoniazid. Isradipine The metabolism of Gefitinib can be decreased when combined with Isradipine. Istradefylline Istradefylline may decrease the excretion rate of Gefitinib which could result in a higher serum level. Itraconazole The metabolism of Gefitinib can be decreased when combined with Itraconazole. Ivacaftor The metabolism of Ivacaftor can be decreased when combined with Gefitinib. Ivermectin Gefitinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The metabolism of Gefitinib can be increased when combined with Ivosidenib Ketoconazole The metabolism of Gefitinib can be decreased when combined with Ketoconazole. Labetalol The metabolism of Gefitinib can be decreased when combined with Labetalol. Lamivudine Gefitinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lansoprazole Lansoprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Lapatinib The metabolism of Lapatinib can be decreased when combined with Gefitinib. Lasmiditan The serum concentration of Gefitinib can be increased when it is combined with Lasmiditan. Ledipasvir Ledipasvir may decrease the excretion rate of Gefitinib which could result in a higher serum level. Leflunomide Gefitinib may decrease the excretion rate of Leflunomide which could result in a higher serum level. Lemborexant The metabolism of Lemborexant can be decreased when combined with Gefitinib. Lenvatinib Gefitinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. Lercanidipine The metabolism of Lercanidipine can be decreased when combined with Gefitinib. Letermovir Letermovir may decrease the excretion rate of Gefitinib which could result in a higher serum level. Levamlodipine The metabolism of Levamlodipine can be decreased when combined with Gefitinib. Levobetaxolol The metabolism of Levobetaxolol can be decreased when combined with Gefitinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Levobupivacaine. Levoketoconazole The metabolism of Gefitinib can be decreased when combined with Levoketoconazole. Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Gefitinib. Levonorgestrel The metabolism of Levonorgestrel can be decreased when combined with Gefitinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Gefitinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Lidocaine. Linagliptin The metabolism of Gefitinib can be decreased when combined with Linagliptin. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Gefitinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Gefitinib. Lisdexamfetamine The metabolism of Lisdexamfetamine can be decreased when combined with Gefitinib. Lisuride The metabolism of Lisuride can be decreased when combined with Gefitinib. Lofexidine The metabolism of Lofexidine can be decreased when combined with Gefitinib. Lonafarnib The metabolism of Gefitinib can be decreased when combined with Lonafarnib. Lopinavir The metabolism of Gefitinib can be decreased when combined with Lopinavir. Lorcaserin The metabolism of Gefitinib can be decreased when combined with Lorcaserin. Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Gefitinib. Lorpiprazole The metabolism of Lorpiprazole can be decreased when combined with Gefitinib. Lovastatin The metabolism of Gefitinib can be decreased when combined with Lovastatin. Lumacaftor The metabolism of Gefitinib can be increased when combined with Lumacaftor. Lumefantrine The metabolism of Gefitinib can be decreased when combined with Lumefantrine. Lusutrombopag Gefitinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Magaldrate Magaldrate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium Magnesium carbonate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium Magnesium hydroxide can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium Magnesium trisilicate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Manidipine The metabolism of Gefitinib can be decreased when combined with Manidipine. Maprotiline The metabolism of Maprotiline can be decreased when combined with Gefitinib. Maribavir Maribavir may decrease the excretion rate of Gefitinib which could result in a higher serum level. Mavacamten The serum concentration of Gefitinib can be decreased when it is combined with Mavacamten. Meclizine The metabolism of Meclizine can be decreased when combined with Gefitinib. Meloxicam The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Meloxicam. Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Gefitinib. Mepivacaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Mepivacaine. Meprednisone The metabolism of Gefitinib can be increased when combined with Meprednisone. Mepyramine The metabolism of Gefitinib can be decreased when combined with Mepyramine. Mesoridazine The metabolism of Mesoridazine can be decreased when combined with Gefitinib. Metamfetamine The metabolism of Metamfetamine can be decreased when combined with Gefitinib. Methadone The metabolism of Gefitinib can be decreased when combined with Methadone. Methantheline Methantheline can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Methimazole The metabolism of Gefitinib can be decreased when combined with Methimazole. Methotrexate Gefitinib may decrease the excretion rate of Methotrexate which could result in a higher serum level. Methotrimeprazine The metabolism of Gefitinib can be decreased when combined with Methotrimeprazine. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gefitinib. Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Gefitinib. Methylene blue The metabolism of Gefitinib can be decreased when combined with Methylene blue. Metoclopramide The metabolism of Gefitinib can be decreased when combined with Metoclopramide. Metoprolol The metabolism of Gefitinib can be decreased when combined with Metoprolol. Metreleptin The metabolism of Gefitinib can be increased when combined with Metreleptin. Metronidazole The metabolism of Metronidazole can be decreased when combined with Gefitinib. Mexiletine The metabolism of Mexiletine can be decreased when combined with Gefitinib. Mianserin The metabolism of Mianserin can be decreased when combined with Gefitinib. Miconazole The metabolism of Gefitinib can be decreased when combined with Miconazole. Midazolam The metabolism of Midazolam can be decreased when combined with Gefitinib. Midostaurin The metabolism of Gefitinib can be increased when combined with Midostaurin. Mifepristone The metabolism of Gefitinib can be decreased when combined with Mifepristone. Milnacipran The metabolism of Gefitinib can be decreased when combined with Milnacipran. Minaprine The metabolism of Minaprine can be decreased when combined with Gefitinib. Mirabegron The serum concentration of Gefitinib can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Gefitinib. Mitotane The metabolism of Gefitinib can be increased when combined with Mitotane. Mitoxantrone Gefitinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Mobocertinib The metabolism of Mobocertinib can be decreased when combined with Gefitinib. Moclobemide The metabolism of Gefitinib can be decreased when combined with Moclobemide. Modafinil The metabolism of Gefitinib can be increased when combined with Modafinil. Mometasone The metabolism of Gefitinib can be increased when combined with Mometasone furoate. Mycophenolate Gefitinib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. Nadolol The metabolism of Nadolol can be decreased when combined with Gefitinib. Naloxone The metabolism of Gefitinib can be decreased when combined with Naloxone. Nateglinide The metabolism of Nateglinide can be decreased when combined with Gefitinib. Nebivolol The metabolism of Nebivolol can be decreased when combined with Gefitinib. Nefazodone The metabolism of Gefitinib can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Gefitinib can be decreased when combined with Nelfinavir. Netupitant The metabolism of Gefitinib can be decreased when combined with Netupitant. Nevirapine The metabolism of Gefitinib can be decreased when combined with Nevirapine. Niacin The metabolism of Gefitinib can be decreased when combined with Niacin. Nicardipine The metabolism of Gefitinib can be decreased when combined with Nicardipine. Nicergoline The metabolism of Nicergoline can be decreased when combined with Gefitinib. Nifedipine The metabolism of Nifedipine can be decreased when combined with Gefitinib. Nilotinib The metabolism of Gefitinib can be decreased when combined with Nilotinib. Nilvadipine The metabolism of Gefitinib can be decreased when combined with Nilvadipine. Nisoldipine The metabolism of Nisoldipine can be decreased when combined with Gefitinib. Nitrendipine The metabolism of Nitrendipine can be decreased when combined with Gefitinib. Nitrofurantoin Gefitinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nizatidine Nizatidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. You Might Also Read Clobetasol Propionate Ointment - Uses, Dosage, Side Effects Norethisterone The metabolism of Norethisterone can be decreased when combined with Gefitinib. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Gefitinib. Novobiocin Novobiocin may decrease the excretion rate of Gefitinib which could result in a higher serum level. Olanzapine Olanzapine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Olaparib The metabolism of Olaparib can be decreased when combined with Gefitinib. Oliceridine The metabolism of Oliceridine can be decreased when combined with Gefitinib. Ombitasvir Gefitinib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. Omeprazole Omeprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Ondansetron The metabolism of Ondansetron can be decreased when combined with Gefitinib. Opium The metabolism of Opium can be decreased when combined with Gefitinib. Oritavancin The metabolism of Gefitinib can be decreased when combined with Oritavancin. Orphenadrine The metabolism of Gefitinib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Gefitinib can be decreased when combined with Osilodrostat. Osimertinib Gefitinib may decrease the excretion rate of Osimertinib which could result in a higher serum level. Ospemifene The metabolism of Gefitinib can be decreased when combined with Ospemifene. Oteseconazole The serum concentration of Gefitinib can be increased when it is combined with Oteseconazole. Oxaliplatin Gefitinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Oxamniquine The metabolism of Gefitinib can be decreased when combined with Oxamniquine. Oxcarbazepine The metabolism of Gefitinib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Oxetacaine. Oxprenolol The metabolism of Gefitinib can be decreased when combined with Oxprenolol. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Gefitinib can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Oxycodone can be decreased when combined with Gefitinib. Oxymorphone The metabolism of Oxymorphone can be decreased when combined with Gefitinib. Ozanimod Gefitinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Gefitinib. Pacritinib The serum concentration of Gefitinib can be increased when it is combined with Pacritinib. Palbociclib Gefitinib may decrease the excretion rate of Palbociclib which could result in a higher serum level. Paliperidone The metabolism of Paliperidone can be decreased when combined with Gefitinib. Palonosetron The metabolism of Palonosetron can be decreased when combined with Gefitinib. Panobinostat The metabolism of Gefitinib can be decreased when combined with Panobinostat. Pantoprazole Pantoprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Parathyroid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Gefitinib. Paritaprevir Paritaprevir may decrease the excretion rate of Gefitinib which could result in a higher serum level. Paroxetine The metabolism of Gefitinib can be decreased when combined with Paroxetine. Pazopanib Gefitinib may decrease the excretion rate of Pazopanib which could result in a higher serum level. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Gefitinib. Peginterferon The metabolism of Gefitinib can be decreased when combined with Peginterferon alfa-2b. Penbutolol The metabolism of Penbutolol can be decreased when combined with Gefitinib. Pentamidine The metabolism of Pentamidine can be decreased when combined with Gefitinib. Pentobarbital The metabolism of Gefitinib can be increased when combined with Pentobarbital. Perampanel The metabolism of Perampanel can be decreased when combined with Gefitinib. Perhexiline The metabolism of Gefitinib can be decreased when combined with Perhexiline. Perphenazine The metabolism of Gefitinib can be decreased when combined with Perphenazine. Phenformin The metabolism of Phenformin can be decreased when combined with Gefitinib. Phenindione Gefitinib may increase the anticoagulant activities of Phenindione. Phenobarbital The metabolism of Gefitinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Phenol. Phenprocoumon Gefitinib may increase the anticoagulant activities of Phenprocoumon. Phenylbutyric acid The metabolism of Gefitinib can be decreased when combined with Phenylbutyric acid. Phenytoin The metabolism of Gefitinib can be increased when combined with Phenytoin. Pibrentasvir Gefitinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. Pimozide The metabolism of Pimozide can be decreased when combined with Gefitinib. Pindolol The metabolism of Pindolol can be decreased when combined with Gefitinib. Piperazine The metabolism of Piperazine can be decreased when combined with Gefitinib. Pipotiazine The metabolism of Gefitinib can be decreased when combined with Pipotiazine. Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Gefitinib. Pitavastatin Gefitinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Pitolisant The serum concentration of Gefitinib can be decreased when it is combined with Pitolisant. Ponatinib The metabolism of Ponatinib can be decreased when combined with Gefitinib. Ponesimod The metabolism of Ponesimod can be decreased when combined with Gefitinib. Posaconazole The metabolism of Gefitinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Gefitinib. Potassium The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Gefitinib. Practolol The metabolism of Practolol can be decreased when combined with Gefitinib. Pralatrexate Gefitinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib Gefitinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level. Pramocaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Pramocaine. Pravastatin Pravastatin may decrease the excretion rate of Gefitinib which could result in a higher serum level. Praziquantel The metabolism of Praziquantel can be decreased when combined with Gefitinib. Prazosin Gefitinib may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednisolone The metabolism of Gefitinib can be increased when combined with Prednisolone phosphate. Prednisone The metabolism of Gefitinib can be increased when combined with Prednisone acetate. Prilocaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Prilocaine. Primaquine The metabolism of Gefitinib can be decreased when combined with Primaquine. Primidone The metabolism of Gefitinib can be increased when combined with Primidone. Procainamide The metabolism of Procainamide can be decreased when combined with Gefitinib. Procaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Procaine. Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Gefitinib. Progesterone Progesterone may decrease the excretion rate of Gefitinib which could result in a higher serum level. Proguanil The metabolism of Gefitinib can be decreased when combined with Proguanil. Promazine The metabolism of Promazine can be decreased when combined with Gefitinib. Promethazine Promethazine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Propafenone The metabolism of Gefitinib can be decreased when combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Propoxycaine. Propranolol The metabolism of Propranolol can be decreased when combined with Gefitinib. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Gefitinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Gefitinib. Quetiapine The metabolism of Quetiapine can be decreased when combined with Gefitinib. Quinidine The metabolism of Gefitinib can be decreased when combined with Quinidine. Quinine The metabolism of Gefitinib can be decreased when combined with Quinine. Rabeprazole Rabeprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Raloxifene Gefitinib may decrease the excretion rate of Raloxifene which could result in a higher serum level. Ranitidine Ranitidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Ranolazine The serum concentration of Gefitinib can be increased when it is combined with Ranolazine. Reboxetine The metabolism of Gefitinib can be decreased when combined with Reboxetine. Regorafenib Regorafenib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Relugolix The metabolism of Relugolix can be decreased when combined with Gefitinib. Remoxipride The metabolism of Remoxipride can be decreased when combined with Gefitinib. Reserpine The metabolism of Gefitinib can be increased when combined with Reserpine. Revefenacin Gefitinib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The metabolism of Gefitinib can be decreased when combined with Ribociclib. Rifampicin The metabolism of Gefitinib can be increased when combined with Rifampicin. Rifamycin The metabolism of Gefitinib can be increased when combined with Rifamycin. Rifapentine The metabolism of Gefitinib can be increased when combined with Rifapentine. Rilonacept The metabolism of Gefitinib can be increased when combined with Rilonacept. Rilpivirine Rilpivirine may decrease the excretion rate of Gefitinib which could result in a higher serum level. Riluzole Gefitinib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Gefitinib. Riociguat Gefitinib may decrease the excretion rate of Riociguat which could result in a higher serum level. Ripretinib Gefitinib may decrease the excretion rate of Ripretinib which could result in a higher serum level. Risperidone The metabolism of Risperidone can be decreased when combined with Gefitinib. Ritonavir The serum concentration of Gefitinib can be increased when it is combined with Ritonavir. Rivaroxaban Gefitinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rolapitant The metabolism of Gefitinib can be decreased when combined with Rolapitant. Romidepsin The metabolism of Romidepsin can be decreased when combined with Gefitinib. Ropeginterferon The metabolism of Gefitinib can be decreased when combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Ropivacaine. Rosuvastatin Gefitinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. Rotigotine The metabolism of Gefitinib can be decreased when combined with Rotigotine. Roxadustat The serum concentration of Gefitinib can be increased when it is combined with Roxadustat. Rucaparib The metabolism of Gefitinib can be decreased when combined with Rucaparib. Rupatadine The metabolism of Rupatadine can be decreased when combined with Gefitinib. Safinamide Safinamide may decrease the excretion rate of Gefitinib which could result in a higher serum level. Salmeterol The metabolism of Salmeterol can be decreased when combined with Gefitinib. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Gefitinib. Saquinavir The metabolism of Gefitinib can be decreased when combined with Saquinavir. Natalizumab The serum concentration of Gefitinib can be decreased when it is combined with Satralizumab. Saxagliptin The metabolism of Saxagliptin can be decreased when combined with Gefitinib. Secukinumab The metabolism of Gefitinib can be increased when combined with Secukinumab. Selegiline The metabolism of Selegiline can be decreased when combined with Gefitinib. Selumetinib Gefitinib may decrease the excretion rate of Selumetinib which could result in a higher serum level. Sertindole The metabolism of Sertindole can be decreased when combined with Gefitinib. Sertraline The metabolism of Sertraline can be decreased when combined with Gefitinib. Sildenafil The metabolism of Gefitinib can be decreased when combined with Sildenafil. Siltuximab The metabolism of Gefitinib can be increased when combined with Siltuximab. Simeprevir The metabolism of Gefitinib can be decreased when combined with Simeprevir. Simvastatin The metabolism of Simvastatin can be decreased when combined with Gefitinib. Sirolimus The metabolism of Sirolimus can be decreased when combined with Gefitinib. Sodium bicarbon Sodium bicarbonate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Sodium zirconium Sodium zirconium cyclosilicate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Sofosbuvir Gefitinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solifenacin The metabolism of Solifenacin can be decreased when combined with Gefitinib. Somatrogon The metabolism of Gefitinib can be increased when combined with Somatrogon. Sorafenib The metabolism of Sorafenib can be decreased when combined with Gefitinib. Sotagliflozin Sotagliflozin may decrease the excretion rate of Gefitinib which could result in a higher serum level. Sotalol The metabolism of Sotalol can be decreased when combined with Gefitinib. Sotorasib The serum concentration of Gefitinib can be decreased when it is combined with Sotorasib. St. John’s Wort The metabolism of Gefitinib can be increased when combined with St. John’s Wort. Stiripentol The metabolism of Gefitinib can be decreased when combined with Stiripentol. Sulfaphenazole The metabolism of Gefitinib can be decreased when combined with Sulfaphenazole. Sulfasalazine Gefitinib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. Sumatriptan Gefitinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The metabolism of Sunitinib can be decreased when combined with Gefitinib. Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Gefitinib. Tadalafil The metabolism of Tadalafil can be decreased when combined with Gefitinib. Tafamidis The serum concentration of Gefitinib can be increased when it is combined with Tafamidis. Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Gefitinib. Talazoparib Gefitinib may decrease the excretion rate of Talazoparib which could result in a higher serum level. Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Gefitinib. Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Gefitinib. Taurocholic acid Taurocholic acid may decrease the excretion rate of Gefitinib which could result in a higher serum level. Tazemetostat Gefitinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. Tegafur The metabolism of Tegafur can be decreased when combined with Gefitinib. Tegaserod The metabolism of Gefitinib can be decreased when combined with Tegaserod. Telaprevir The metabolism of Gefitinib can be decreased when combined with Telaprevir. Telithromycin The metabolism of Gefitinib can be decreased when combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Gefitinib which could result in a higher serum level. Telotristat ethyl The serum concentration of Gefitinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Gefitinib. Teniposide The metabolism of Teniposide can be decreased when combined with Gefitinib. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gefitinib. Tepotinib Tepotinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Terbinafine The metabolism of Gefitinib can be decreased when combined with Terbinafine. Terfenadine The metabolism of Gefitinib can be decreased when combined with Terfenadine. Teriflunomide Gefitinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Gefitinib. Testosterone Gefitinib may decrease the excretion rate of Testosterone which could result in a higher serum level. Testosterone Gefitinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone Gefitinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Tetrabenazine The metabolism of Tetrabenazine can be decreased when combined with Gefitinib. Tetracaine The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Tetracaine. Tezacaftor The metabolism of Tezacaftor can be decreased when combined with Gefitinib. Thalidomide The metabolism of Gefitinib can be increased when combined with Thalidomide. Theophylline The metabolism of Theophylline can be decreased when combined with Gefitinib. Thioridazine The metabolism of Gefitinib can be decreased when combined with Thioridazine. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Gefitinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Gefitinib. Ticagrelor The metabolism of Ticagrelor can be decreased when combined with Gefitinib. Ticlopidine The metabolism of Gefitinib can be decreased when combined with Ticlopidine. Timolol The metabolism of Timolol can be decreased when combined with Gefitinib. Tiotropium The metabolism of Tiotropium can be decreased when combined with Gefitinib. Tipranavir The metabolism of Gefitinib can be decreased when combined with Tipranavir. Tivozanib Tivozanib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Tocilizumab The metabolism of Gefitinib can be increased when combined with Tocilizumab. Tolterodine The metabolism of Tolterodine can be decreased when combined with Gefitinib. Topotecan Gefitinib may decrease the excretion rate of Topotecan which could result in a higher serum level. Trabectedin The metabolism of Trabectedin can be decreased when combined with Gefitinib. You Might Also Read Chlorambucil - Uses, Dosage, Side Effects, Interaction Tramadol The metabolism of Tramadol can be decreased when combined with Gefitinib. Tranylcypromine The metabolism of Gefitinib can be decreased when combined with Tranylcypromine. Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Gefitinib. Trazodone The metabolism of Trazodone can be decreased when combined with Gefitinib. Tretinoin The metabolism of Tretinoin can be decreased when combined with Gefitinib. Triamcinolone The metabolism of Gefitinib can be increased when combined with Triamcinolone. Triazolam The metabolism of Triazolam can be decreased when combined with Gefitinib. Triclabendazole The metabolism of Gefitinib can be decreased when combined with Triclabendazole. Trilaciclib Gefitinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimipramine The metabolism of Trimipramine can be decreased when combined with Gefitinib. Tripelennamine The metabolism of Gefitinib can be decreased when combined with Tripelennamine. Troglitazone The metabolism of Gefitinib can be decreased when combined with Troglitazone. Troleandomycin The metabolism of Gefitinib can be decreased when combined with Troleandomycin. Trospium The metabolism of Gefitinib can be decreased when combined with Trospium. Tucatinib The metabolism of Tucatinib can be decreased when combined with Gefitinib. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Gefitinib. Udenafil The metabolism of Udenafil can be decreased when combined with Gefitinib. Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Gefitinib. Valbenazine The metabolism of Valbenazine can be decreased when combined with Gefitinib. Vandetanib Vandetanib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Vardenafil The metabolism of Vardenafil can be decreased when combined with Gefitinib. Velpatasvir Gefitinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. Vemurafenib Gefitinib may decrease the excretion rate of Vemurafenib which could result in a higher serum level. Venetoclax The metabolism of Gefitinib can be decreased when combined with Venetoclax. Venlafaxine The metabolism of Gefitinib can be decreased when combined with Venlafaxine. Verapamil The metabolism of Gefitinib can be decreased when combined with Verapamil. Vernakalant The metabolism of Vernakalant can be decreased when combined with Gefitinib. Vilazodone The metabolism of Gefitinib can be decreased when combined with Vilazodone. Viloxazine The metabolism of Gefitinib can be decreased when combined with Viloxazine. Vinblastine The metabolism of Gefitinib can be decreased when combined with Vinblastine. Vincristine The metabolism of Vincristine can be decreased when combined with Gefitinib. Vinorelbine Gefitinib may increase the neutropenic activities of Vinorelbine. Vismodegib Vismodegib may decrease the excretion rate of Gefitinib which could result in a higher serum level. Vonoprazan Vonoprazan can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Voriconazole The serum concentration of Gefitinib can be increased when it is combined with Voriconazole. Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Gefitinib. Voxilaprevir Gefitinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. Warfarin Gefitinib may increase the anticoagulant activities of Warfarin. Yohimbine The metabolism of Yohimbine can be decreased when combined with Gefitinib. Zaleplon The metabolism of Zaleplon can be decreased when combined with Gefitinib. Zidovudine Gefitinib may decrease the excretion rate of Zidovudine which could result in a higher serum level. Zimelidine The metabolism of Gefitinib can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Gefitinib can be decreased when combined with Ziprasidone. Zolpidem The metabolism of Zolpidem can be decreased when combined with Gefitinib. Zonisamide The metabolism of Zonisamide can be decreased when combined with Gefitinib. Zuclopenthixol The metabolism of Zuclopenthixol can be decreased when combined with Gefitinib. Pregnancy and Lactation AU TGA pregnancy category: C US FDA pregnancy category: Not assigned. Pregnancy Based on its mechanism of action and animal data, IRESSA can cause fetal harm when administered to a pregnant woman. In animal reproductive studies, oral administration of gefitinib from organogenesis through weaning resulted in fetotoxicity and neonatal death at doses below the recommended human dose (see Animal Data). Advise pregnant women of the potential hazard to a fetus or potential risk for loss of the pregnancy. The background risk of major birth defects and miscarriage for the indicated population is unknown; however, the background risk in the U.S. general population of major birth defects is 2-4% and miscarriage is 15-20% of clinically recognized pregnancies Lactation No information is available on the clinical use of gefitinib during breastfeeding. Because gefitinib is 90% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 48 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during gefitinib therapy. How should this medicine be used? Gefitinib comes as a tablet to take by mouth. It is usually taken with or without food once a day. Take gefitinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take gefitinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. If you are unable to swallow the tablets, you may dissolve them in water. Place one tablet in 4 to 8 ounces (120 to 240 mL) of plain, noncarbonated drinking water. Stir with a spoon for about 15 minutes until the tablet is dissolved. Drink the mixture right away. Rinse the glass with another 4 to 8 ounces (120 to 240 mL) of water and drink the rinse water right away to be sure that you swallow all of the medication. Your doctor may delay or permanently stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with gefitinib. What special precautions should I follow? Before taking gefitinib, tell your doctor and pharmacist if you are allergic to gefitinib, any other medications, or any of the ingredients in gefitinib tablets. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: anticoagulants (‘blood thinners) such as warfarin (Coumadin, Jantoven); antifungals such as itraconazole (Onmel, Sporanox) and ketoconazole (Nizoral); metoprolol (Lopressor, Toprol XL, in Dutoprol); phenytoin (Dilantin, Phenytek); and tricyclic antidepressants such as imipramine (Tofranil) and amitriptyline. Many other medications may interact with gefitinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. if you are taking an antacid or an H2 blocker medication for indigestion, heartburn, or ulcers such as cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), or ranitidine (Zantac), take them at least 6 hours before or 6 hours after taking gefitinib. if you are taking a proton pump inhibitor medication for indigestion, heartburn, or ulcers such as esomeprazole (Nexium), lansoprazole (Prevacid), omeprazole (Prilosec), pantoprazole (Protonix), or rabeprazole (AcipHex), take it at least 12 hours before or at least 12 hours after taking gefitinib. tell your doctor if you have or have ever had pulmonary fibrosis (scarring of the lungs) or other lung or breathing problems, eye or vision problems, or liver disease. tell your doctor if you are pregnant or plan to become pregnant. Gefitinib may cause infertility (difficulty becoming pregnant) in females. However, you should use birth control to prevent pregnancy during your treatment with gefitinib and for at least 2 weeks after you stop taking the medication. If you become pregnant while taking gefitinib, call your doctor. Gefitinib may harm the fetus and increase the risk of pregnancy loss. tell your doctor if you are breastfeeding. You should not breastfeed while you are taking gefitinib. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021399lbl.pdf https://pubchem.ncbi.nlm.nih.gov/compound/Gefitinib https://pubchem.ncbi.nlm.nih.gov/compound/Gefitinib-monohydrate https://pubchem.ncbi.nlm.nih.gov/compound/19077503 https://go.drugbank.com/drugs/DB00317 https://www.drugs.com/mtm/gefitinib.html https://www.mayoclinic.org/drugs-supplements/gefitinib-oral-route/side-effects/drg-20150913 https://medlineplus.gov/druginfo/meds/a607002.html https://en.wikipedia.org/wiki/Gefitinib https://www.webmd.com/drugs/2/drug-75201/gefitinib-oral/details/list-contraindications ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL939/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Chemical Probes Portal Gefitinib https://www.chemicalprobes.org/gefitinib Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp Gefitinib https://ctdbase.org/detail.go?type=chem&acc=D000077156 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads GEFITINIB https://www.dgidb.org/drugs/GEFITINIB DrugBank https://www.drugbank.ca/legal/terms_of_use Gefitinib https://www.drugbank.ca/drugs/DB00317 IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license gefitinib https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4941 https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Gefitinib http://idrblab.net/ttd/data/drug/details/D09XZB CAS Common Chemistry https://creativecommons.org/licenses/by-nc/4.0/ Gefitinib https://commonchemistry.cas.org/detail?cas_rn=184475-35-2 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Gefitinib [USAN:INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0184475352 https://chem.nlm.nih.gov/chemidplus/ DTP/NCI https://www.cancer.gov/policies/copyright-reuse Gefitinib https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=759856 Gefitinib https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=715055 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Gefitinib https://comptox.epa.gov/dashboard/DTXSID8041034 https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/175956 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking GEFITINIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/S65743JHBS Human Metabolome Database (HMDB). http://www.hmdb.ca/citing Gefitinib http://www.hmdb.ca/metabolites/HMDB0014462 HMDB0014462_msms_374198 https://hmdb.ca/metabolites/HMDB0014462#spectra ChEBI Gefitinib http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49668 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking GEFITINIB https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Gefitinib https://www.ncbi.nlm.nih.gov/books/n/livertox/Gefitinib/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1855 NCI Thesaurus Tree https://ncit.nci.nih.gov ClinicalTrials.gov. https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html GEFITINIB https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=GEFITINIB Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking gefitinib https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/21317853 https://pubchem.ncbi.nlm.nih.gov/substance/53799235 European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Iressa (EMEA/H/C/001016) https://www.ema.europa.eu/en/medicines/human/EPAR/iressa NORMAN Suspect List Exchange https://creativecommons.org/licenses/by/4.0/ gefitinib NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ Drugs and Lactation Database (LactMed) LICENSE https://www.nlm.nih.gov/copyright.html Gefitinib https://www.ncbi.nlm.nih.gov/books/NBK500852/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking GEFITINIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NIST Mass Spectrometry Data Center LICENSE https://www.nist.gov/srd/public-law Iressa http://www.nist.gov/srd/nist1a.cfm MassBank of North America (MoNA) https://mona.fiehnlab.ucdavis.edu/documentation/license Gefitinib (Iressa) https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22XGALLCVXEZPNRQ-UHFFFAOYSA-N%22%27 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Gefitinib https://www.cancer.gov/about-cancer/treatment/drugs/gefitinib NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html gefitinib https://rxnav.nlm.nih.gov/id/rxnorm/328134 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/IRE PubChem https://pubchem.ncbi.nlm.nih.gov PFAS and Fluorinated Compounds in PubChem https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=31052058-695535643 https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=31052073-852550032 The Cambridge Structural Database https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=259805 https://www.ccdc.cam.ac.uk/structures/Search?Ccdcid=819492 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=31052058-695535643 https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=31052063-430273923 WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Gefitinib https://list.essentialmeds.org/medicines/403 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Gefitinib https://www.wikidata.org/wiki/Q417824 Wiley https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=115072 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Gefitinib https://www.ncbi.nlm.nih.gov/mesh/2027915 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents https://www.ncbi.nlm.nih.gov/mesh/68000970 Protein Kinase Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68047428 KEGG https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drugs listed in the Japanese Pharmacopoeia http://www.genome.jp/kegg-bin/get_htext?br08311.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg Drug Classes http://www.genome.jp/kegg-bin/get_htext?br08332.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html PATENTSCOPE (WIPO) SID 389147678 https://pubchem.ncbi.nlm.nih.gov/substance/389147678 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More